Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study

BACKGROUND: To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer’s disease, supportive biomarker information is necessary. This study was aimed to investigate the association of plasma amyloid-beta (Aβ) levels with the presence of pathological accumulat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Alzheimers Res Ther
Autors principals: Pérez-Grijalba, Virginia, Arbizu, Javier, Romero, Judith, Prieto, Elena, Pesini, Pedro, Sarasa, Leticia, Guillen, Fernando, Monleón, Inmaculada, San-José, Itziar, Martínez-Lage, Pablo, Munuera, Josep, Hernández, Isabel, Buendía, Mar, Sotolongo-Grau, Oscar, Alegret, Montserrat, Ruiz, Agustín, Tárraga, Lluis, Boada, Mercè, Sarasa, Manuel
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6886187/
https://ncbi.nlm.nih.gov/pubmed/31787105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-019-0549-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars